← Back to Search

Progestin

Contraceptive Implant for Birth Control (NextOC2 Trial)

Phase 4
Waitlist Available
Led By Melissa C Matulich, MD MAS
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights

NextOC2 Trial Summary

This trial is testing whether a contraceptive implant is more effective than the pill in women who are already using birth control.

Who is the study for?
This trial is for women over 18 who are currently using combined oral contraceptives (COCs) or about to start them. It's not suitable for those with conditions that make COCs or contraceptive implants risky, anyone in another clinical trial recently, or within 2 weeks post-pregnancy.Check my eligibility
What is being tested?
The study tests the Nexplanon implant in women who choose COCs for birth control. Participants will receive the implant and be monitored for a year to see if they stick with it, return to COCs, use both, and to note any changes in bleeding patterns and adverse events.See study design
What are the potential side effects?
Possible side effects include irregular bleeding patterns, discomfort at the implant site, potential hormonal side effects similar to those of oral contraceptives such as mood swings, weight gain, headaches, acne or breast tenderness.

NextOC2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Evaluating ENG Implant as Acceptable
Secondary outcome measures
Bleeding Patterns
Number of Participants Continuing COC
Number of Participants Evaluating ENG as Tolerable: Tolerability
+1 more

NextOC2 Trial Design

1Treatment groups
Experimental Treatment
Group I: COC users or new startsExperimental Treatment1 Intervention
Subjects will have an etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women using COC for less than 1 month will be considered new starts.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Etonogestrel contraceptive implant
2010
Completed Phase 4
~290

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
914 Previous Clinical Trials
4,720,595 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,907 Previous Clinical Trials
5,065,916 Total Patients Enrolled
University of PennsylvaniaOTHER
2,016 Previous Clinical Trials
42,873,976 Total Patients Enrolled

Media Library

Etonogestrel contraceptive implant (Progestin) Clinical Trial Eligibility Overview. Trial Name: NCT04423055 — Phase 4
Birth Control Research Study Groups: COC users or new starts
Birth Control Clinical Trial 2023: Etonogestrel contraceptive implant Highlights & Side Effects. Trial Name: NCT04423055 — Phase 4
Etonogestrel contraceptive implant (Progestin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04423055 — Phase 4
~25 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top